24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
@Finance
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
EpiPen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
18:20
The World Cup warning: Riots don’t start in the streets. They start online
18:07
“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal
14:18
"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"
13:32
“There is no better solution for Zim than the one we created”
More stories
Buzz
Most popular
Daily
Weekly
1
"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"
2
Iron Dome and Iron Beam maker Rafael unveils new weapon against the drone threat
3
"If there is no significant change, we will see a 25%-30% reduction in high-tech's workforce"
4
Echo: “Employees have become very good at identifying performative culture”
5
“There’s a price where you have to say yes”: CyberArk founder on the $25 billion Palo Alto deal
More news
EpiPen
4 stories about EpiPen
Teva Jumps on NYSE on a Bit of Good News
21.08.19
|
Hezi Sternlicht
An opioid-abuse lawsuit settlement reached by drugmakers Endo and Allergan Tuesday could bode well for Teva’s legal future, as does the release of an FDA-approved generic version of EpiPen JR
Teva, Mylan Drop on Announcement of Epinephrine Injector Rival
09.12.18
|
Lilach Baumer
Novartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
Teva’s Generic EpiPen Now Available in the U.S. in Limited Numbers
28.11.18
|
Lilach Baumer
In August, the Israel-headquartered drugmaker won approval to market the first generic EpiPen auto-injectors in the U.S.
Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says
26.08.18
|
Dror Reich
The Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month